Lyra Therapeutics Current Valuation vs. Cash Per Share
| LYRA Stock | USD 0.21 0.02 10.53% |
For Lyra Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lyra Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lyra Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lyra Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lyra Therapeutics over time as well as its relative position and ranking within its peers.
Lyra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lyra Therapeutics Cash Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lyra Therapeutics's current stock value. Our valuation model uses many indicators to compare Lyra Therapeutics value to that of its competitors to determine the firm's financial worth. Lyra Therapeutics is rated below average in current valuation category among its peers. It is rated below average in cash per share category among its peers . At present, Lyra Therapeutics' Cash Per Share is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lyra Therapeutics' earnings, one of the primary drivers of an investment's value.Lyra Current Valuation vs. Competition
Lyra Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 1.75 Billion. Lyra Therapeutics has negative current valuation of (2.24 Million) having no influence on the industry.
Lyra Cash Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Lyra Therapeutics |
| = | (2.24 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Lyra Therapeutics |
| = | 3.79 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Lyra Cash Per Share Comparison
Lyra Therapeutics is currently under evaluation in cash per share category among its peers.
Lyra Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lyra Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lyra Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Lyra Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Lyra Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 33 K | 34.6 K | |
| Net Interest Income | 4.1 M | 4.3 M | |
| Interest Income | 4.1 M | 4.3 M | |
| Operating Income | -67.1 M | -63.8 M | |
| Net Loss | -61.8 M | -58.7 M | |
| Income Before Tax | -62.6 M | -59.5 M | |
| Total Other Income Expense Net | 4.5 M | 4.7 M | |
| Net Loss | -49.8 M | -47.3 M | |
| Net Loss | -62.7 M | -59.5 M | |
| Income Tax Expense | 59 K | 62 K | |
| Non Operating Income Net Other | 73.8 K | 65.6 K | |
| Change To Netincome | 7.2 M | 7.6 M | |
| Net Loss | (1.26) | (1.32) | |
| Income Quality | 1.01 | 0.97 | |
| Net Income Per E B T | 1.00 | 0.79 |
Lyra Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lyra Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lyra Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lyra Therapeutics' important profitability drivers and their relationship over time.
Use Lyra Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lyra Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyra Therapeutics will appreciate offsetting losses from the drop in the long position's value.Lyra Therapeutics Pair Trading
Lyra Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Lyra Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lyra Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lyra Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lyra Therapeutics to buy it.
The correlation of Lyra Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lyra Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lyra Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lyra Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lyra Therapeutics position
In addition to having Lyra Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project Lyra Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lyra Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lyra Therapeutics' income statement, its balance sheet, and the statement of cash flows.